https://doi.org/10.4081/bse.164
Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity
Published: 29 September 2021
Abstract Views: 473
PDF: 265
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
New disruptors of the ERCC1-XPF interaction interaction have a synergistic effect with traditional NER inhibitors, in p53 positive cells. Furthermore, the synergy can be resumed in p53 negative cells upon reactivation of the TP53 gene.
[1] Gentile, F, Elmenoufy, AH, Ciniero, G, et al. Computer-aided drug design of small molecule inhibitors of the ERCC1-XPF protein–protein interaction. Chem Biol Drug Des 2020;95:460– 71.
[2] Jordheim LP, Barakat KH, Heinrich-Balard L, et al. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol Pharmacol 2013;84:12-24.
[3] Friboulet L, Soria JC, Olaussen KA. The “Guardian of the Genomeâ€â€”An Old Key to Unlock the ERCC1 Issue. Clin Cancer Res 2019;25:2369-71.
[4] Ciniero G, Elmenoufy AH, Gentile F, et al. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair. Cancer Chemother Pharmacol 2021;87:259-67.
[2] Jordheim LP, Barakat KH, Heinrich-Balard L, et al. Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells. Mol Pharmacol 2013;84:12-24.
[3] Friboulet L, Soria JC, Olaussen KA. The “Guardian of the Genomeâ€â€”An Old Key to Unlock the ERCC1 Issue. Clin Cancer Res 2019;25:2369-71.
[4] Ciniero G, Elmenoufy AH, Gentile F, et al. Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair. Cancer Chemother Pharmacol 2021;87:259-67.
How to Cite
Ciniero, G., Gentile, F., Elmenoufy, A. H., Cros-Perrial, E. ., West, F. G., Weinfeld, M., … Tuszynski, J. A. (2021). Targeting cancer drug resistance by modulation of ERCC1-XPF and p53 activity. Biomedical Science and Engineering, 2(1). https://doi.org/10.4081/bse.164
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Jack A. Tuszynski, Edward A. Rietman, How systems biology of cancer signaling pathways can inform optimized combination chemotherapy design , Biomedical Science and Engineering: Vol. 3 No. 1 (2022)
- Gianvito Grasso, Lorenzo Pallante, Jack A. Tuszynski, Umberto Morbiducci, Marco A. Deriu, Computational molecular modelling as a platform for a deeper understanding of protein dynamics and rational drug design , Biomedical Science and Engineering: Vol. 1 No. 1 (2020)
- Michela Sperti, Fabrizio D'Ascenzo, Luca Navarini, Giacomo Di Benedetto, Antonella Afeltra, Roberto Giacomelli, Marco A. Deriu, Machine learning approaches as an alternative to traditional statistical methods in cardiovascular risk prediction , Biomedical Science and Engineering: Vol. 2 No. 1 (2021)
- Marcello Miceli, Cecile Exertier, Beatrice Vallone, Marco Cavaglià, Marco A. Deriu, Elucidating molecular connection between IAHSP onset and Alsin protein by means of homology modelling and molecular dynamics , Biomedical Science and Engineering: Vol. 2 No. 1 (2021)
- Eric A. Zizzi, Marco Cavaglià, Marco A. Deriu, Jack A. Tuszynski, In silico investigation of molecular interactions of volatile anesthetics: effects on phospholipid membranes and subcellular targets , Biomedical Science and Engineering: Vol. 2 No. 1 (2021)
Similar Articles
- Salvatore Simmini, Allen C. Eaves, Sharon A. Louis, Wing Chang, Human pluripotent stem cell-derived organoids and their potential to reduce the use of animal models in research , Biomedical Science and Engineering: Vol. 3 No. 1 (2022)
- Monica Boffito, Arianna Grivet Brancot, Ornella Lima, Simona Bronco, Susanna Sartori, Gianluca Ciardelli, Injectable thermosensitive gels for the localized and controlled delivery of biomolecules in tissue engineering/regenerative medicine , Biomedical Science and Engineering: Vol. 1 No. 1 (2020)
- S. Motta, L. Callea, L. Bonati, Insights from computational studies in drug design and toxicity assessment , Biomedical Science and Engineering: Vol. 5 No. 1 (2024)
You may also start an advanced similarity search for this article.
